Loading...
XKRX
063160
Market cap57mUSD
Oct 08, Last price  
14,010.00KRW
1D
-7.03%
1Q
4.71%
Jan 2017
-37.54%
IPO
294.09%
Name

CKD Bio Corp

Chart & performance

D1W1MN
XKRX:063160 chart
P/E
—
P/S
0.48
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.29%
Rev. gr., 5y
5.14%
Revenues
160.07b
-6.80%
66,409,841,00083,393,222,000106,553,579,000121,568,352,000110,527,721,450113,759,577,680100,370,797,420106,389,740,550106,690,657,800113,013,402,140118,187,072,160124,510,019,000137,184,188,550124,599,959,410142,238,418,400156,042,327,040160,352,778,354171,756,009,000160,070,987,000
Net income
-2.89b
L
-3,273,392,0008,737,629,00016,183,929,00014,375,712,00010,920,596,3707,101,290,0801,657,448,850-1,105,050,1406,653,133,0009,434,614,7508,016,298,6207,956,187,16012,264,879,9606,207,398,430-6,576,601,340-16,702,615,620-24,192,519,6408,700,827,000-2,888,351,000
CFO
-4.14b
L
408,087,00010,689,037,00026,573,028,00023,887,459,00012,963,470,55022,900,061,37010,924,090,05011,222,959,39014,338,941,94015,500,000,86020,445,524,66015,535,533,73016,990,277,0004,824,020,040-5,882,180,150-3,204,562,880-7,223,883,84414,031,126,000-4,142,995,000
Dividend
Dec 27, 2024100 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

CKD Bio Corp., a South Korean company founded in 1941 and headquartered in Seoul, specializes in the production and distribution of pharmaceutical active ingredients (APIs). Their manufacturing processes leverage diverse technologies, including fermentation, chemical synthesis, and biotechnology. The company's extensive portfolio of APIs targets a broad spectrum of therapeutic applications, encompassing antibiotics, beta-lactamase inhibitors, immunosuppressants, oncology treatments, anti-obesity medications, dry eye remedies, antiviral and antituberculosis agents, antihyperlipidemics, and probiotics. Beyond its core manufacturing, CKD Bio Corp. also provides contract research, development, and manufacturing (CRDMO) services for APIs, pharmaceutical intermediates, and probiotic formulations. The company actively exports its products, establishing a global reach.

Key people

Hak Yeon Hwang
Assistant Managing Director
Hae Mun Lee
Internal Auditor
Joeng Jin Lee
Chief Executive Officer, Director · since 2017
Assistant Managing Director · since 2012
Gwang Seop Gil
Non-Executive Independent Director · since 2008
IPO date
Dec 11, 2001
Employees
Domiciled in
KR
Incorporated in
KR
Headquarters & legal address
서울특별시 서대문구 충정로 8
5층
Seoul, 11 03742
KR
Address
8, Chungjeong-ro, Seodaemun-gu, Seoul
5F
Seoul, 11 03742
KR
Other language
CKD Bio Corporation

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT